HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Rifaksimin in complex treatment of Helicobacter pylori infection in children (a pilot study)].

AbstractAIM:
To provide a pilot study of empiric rifaximin, bismuth subcitrate, furazolidone/nifuratel triple therapy for H. pylori gastritis in childhood.
MATERIALS AND METHODS:
Forty one pediatric outpatients (27 females, mean age 14.5+/-1.4 ys) with H. pylori-associated chronic gastritis who underwent endoscopy for dyspeptic symptoms received the combination of bismuth subcitrate (8 mg/kg/day, q. d. s.) for 14 days, rifaximin (800 mg/day) for 10 days and furazolidone (10 mg/kg/day, q. d. s.) or nifuratel (15 mg/kg/two times daily) for 10 days. H. pylori status was determined before the treatment by modified Giemsa staining/urease test and after the treatment (in 4-6 weeks) by ammonia breath test.
RESULTS:
H. pylori was eradicated in 35 children (85.4%; 95%CI: 75.4-96.4 ITT and PP tests). There were no serious adverse reactions and were no withdrawals due to any side effects.
CONCLUSION:
The combination of rifaximin, bismuth subcitrate and furazolidone/nifuratel was an effective and tolerable regimen for initial H. pylori eradication.
AuthorsA A Nizhevich, P L Shcherbakov, E N Akhmadeeva
JournalEksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology (Eksp Klin Gastroenterol) Issue 3 Pg. 98-100 ( 2009) ISSN: 1682-8658 [Print] Russia (Federation)
PMID19928007 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Anti-Infective Agents
  • Organometallic Compounds
  • Rifamycins
  • Furazolidone
  • bismuth tripotassium dicitrate
  • Rifaximin
  • Nifuratel
Topics
  • Adolescent
  • Anti-Infective Agents (administration & dosage, therapeutic use)
  • Breath Tests
  • Child
  • Drug Therapy, Combination
  • Female
  • Furazolidone (administration & dosage, therapeutic use)
  • Helicobacter Infections (drug therapy, microbiology)
  • Helicobacter pylori (drug effects, isolation & purification)
  • Humans
  • Male
  • Nifuratel (administration & dosage, therapeutic use)
  • Organometallic Compounds (administration & dosage, therapeutic use)
  • Pilot Projects
  • Rifamycins (administration & dosage, therapeutic use)
  • Rifaximin
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: